Skip to main content
. 2020 Oct 1;148:e241. doi: 10.1017/S0950268820002368

Table 1.

Baseline characteristics of study population

Variables All Survivors Non-survivors P value
(N = 74) (N = 43) (N = 31)
Demographics and clinical characteristics
Age (years) 64 (56, 72) 60 (50, 68) 68 (63, 79) 0.001**
Gender (male%) 43 (58.1) 22 (51.1) 21 (67.7) 0.15
Living in Wuhan (%) 66 (89.19) 41 (95.35) 25 (80.65) 0.04*
Hypertension (%) 23 (31.0) 14 (32.5) 9 (29.0) 0.75
Diabetes (%) 13 (17.5) 9 (20.9) 4 (12.9) 0.37
Length of stay (days) 15.5 (9, 27) 21 (15, 34) 8 (4, 14) <0.0001**
Symptoms and vital signs on admission
Cough (%) 52 (70.27) 30 (69.77) 22 (70.97) 0.91
Fever (%) 57 (77.03) 33 (76.74) 24 (77.42) 0.95
Dyspnoea (%) 40 (54.05) 15 (34.88) 25 (80.65) <0.0001**
Confusion (%) 9 (12.16) 1 (2.33) 8 (25.81) 0.002**
Temperature (°C) 36.6 (36.2, 37.5) 36.5 (36.1, 36.8) 36.95 (36.3, 37.9) 0.03*
Respiratory rate ⩾24 bpm 19 (26.39%) 3 (7.32%) 16 (51.61%) <0.0001**
Heart rate (bpm) 86 (78, 100) 84 (77, 96) 90 (82, 110) 0.02*
SO2 < 90% on admission 10 (15.15%) 1 (2.5%) 9 (34.62%) 0.0004**
SBP (mmHg) 131 (120, 146) 130 (120, 141) 140 (126, 156) 0.17
DBP (mmHg) 96 (91, 98) 97 (94, 98) 90.5 (81, 95) 0.18
Radiology
Bilateral patchy shadowing in chest CT 72 (98.63%) 42 (97.67%) 30 (100%) 0.4
Laboratory results
Complete blood count (CBC)
WBC (×109/l) 6.73 (5.19, 8.24) 6.29 (4.91, 7.62) 8.2 (5.93, 10.93) 0.002**
Neutrophil (×109/l) 5.55 (3.96, 7.2) 4.44 (3.63, 5.79) 7.21 (5.28, 10.11) <0.0001**
Lymphocyte(×109/l) 0.89 (0.58, 1.37) 1.09 (0.84, 1.42) 0.66 (0.42, 0.88) 0.0002**
NLR 6.51 (3.43, 10.28) 4.13 (2.4, 6.58) 10.29 (7.25, 20.93) <0.0001**
Monocyte (×109/l) 0.37 (0.24, 0.54) 0.42 (0.33, 0.6) 0.27 (0.2, 0.39) 0.003**
Haemoglobin (g/dl) 126 (111, 142) 123.5 (115, 145) 127 (105, 137) 0.72
Platelet (×109/l) 190 (153, 235) 207.5 (168, 258) 162 (120, 213) 0.006**
Inflammatory or tissue injury markers
C reactive protein (mg/l) 40.95 (10.63, 92.29) 25.29 (4.78, 55.1) 85.07 (53.59, 115.225) <0.0001**
Lactic dehydrogenase (U/l) 370 (214.5, 531.5) 252 (185.5, 327) 541 (443.5, 602) <0.0001**
 α-Hydroxybutyrate dehydrogenase (U/l) 306.5 (170, 449) 201 (149, 250) 449 (360, 505) <0.0001**
Liver and renal function
Alanine aminotransferase (U/l) 33.5 (23, 52) 29.5 (21, 48) 48 (28.5, 69) 0.01*
Aspartate aminotransferase (U/l) 35 (22, 49) 29.5 (20, 40) 48 (30, 72.5) 0.001**
Serum pre-albumin (mg/l) 131.4 (85.9, 209.9) 171.1 (115.7, 247.6) 85.9 (61.1, 129.1) <0.0001**
Serum albumin (g/l) 29.4 (25.4, 33.8) 32.65 (26.8, 38.4) 26.55 (24.4, 28.65) <0.0001**
BUN (mmol/l) 6.41 (4.39, 10.09) 5.35 (3.78, 7.78) 8.91 (5.97, 14.48) 0.001**
eGFR (ml/min) 90.74 (68.92, 111.717) 93.4 (67.71, 118.465) 77.81 (71.6, 97.739) 0.14
Cardiac injury markers
CK (U/l) 78.5 (45, 170) 54.5 (39, 99) 149.5 (75, 251.5) 0.001**
CK-MB (U/l) 13 (10, 20) 11 (8.5, 14) 19 (13, 23) <0.0001**
Coagulation
Prothrombin time (s) 13.55 (12.7, 14.7) 13.1 (12.5, 13.9) 14.3 (13.5, 15.1) 0.002**
Activated partial thromboplastin time (s) 37.15 (33.5, 42.3) 36.6 (33.5, 40.1) 39.2 (34.2, 43) 0.30
D-Dimer (μg/ml) 0.86 (0.3, 6) 0.5 (0.26, 1.685) 8 (1.53, 8) 0.0002**
CURB-65 score <0.0001**
0–1 45 (60.81%) 35 (81.40%) 10 (32.26%)
2 21 (28.38%) 8 (18.60%) 13 (41.94%)
⩾3 8 (10.81%) 0 8 (25.81%)